Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 3/20 | 0.39 |
| ▸ | INSR | P06213 | 3/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12071970 | 0.91 | BTK (0.48) | BTKJAK2MAOA | |
| SCHEMBL9983661 | 0.89 | BTK (0.47) | BTKJAK2 | |
| SCHEMBL9984004 | 0.89 | BTK (0.47) | BTKJAK2 | |
| SCHEMBL12072012 | 0.87 | BTK (0.48) | BTKJAK2 | |
| SCHEMBL9983495 | 0.87 | BTK (0.50) | BTKJAK2 | |
| SCHEMBL12070558 | 0.85 | BTK (0.45) | BTKJAK2 | |
| SCHEMBL9983684 | 0.84 | BTK (0.52) | BTKJAK2 | |
| SCHEMBL9983506 | 0.84 | BTK (0.52) | BTKJAK2 | |
| SCHEMBL12070652 | 0.83 | BTK (0.51) | BTKJAK2MAOA | |
| SCHEMBL12070555 | 0.83 | BTK (0.48) | BTKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582668-B1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2582668-B1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-2582668-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, PRKACA, CILK1 | BTK 1/4885JAK2 10/4885MAOA 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.